ConductScience.org, home

Paper40201353

Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report.

Li X and 7 others. Front Oncol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report. Papers, record 40201353. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40201353

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report.
PubMed
Journal
Front Oncol
PubMed
Year
2025
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-04-10
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li XXiaoqing
2Ma SSuhua
3She QQing
4Liu ZZirong
5Liu YYanan
6Kuang YYanjing
7Huang XXiaozhun
8Zhan ZZhengyin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133651422First case of lenvatinib-induced pyoderma gangrenosum: Possible management with dose reduction.J Dermatol2021https://conductscience.org/library/papers/33651422PubMed
229192996British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017.Br J Dermatol2017https://conductscience.org/library/papers/29192996PubMed
316990857Mechanisms of cutaneous toxicities to EGFR inhibitors.Nat Rev Cancer2006https://conductscience.org/library/papers/16990857PubMed
438039993Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.Lancet Oncol2023https://conductscience.org/library/papers/38039993PubMed
529433850Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018https://conductscience.org/library/papers/29433850PubMed
628589639Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma.J Gastroenterol Hepatol2018https://conductscience.org/library/papers/28589639PubMed
722004366Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis.J Gastroenterol Hepatol2012https://conductscience.org/library/papers/22004366PubMed
838650037Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.BMC Med2024https://conductscience.org/library/papers/38650037PubMed
937426368Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma.Dermatol Reports2023https://conductscience.org/library/papers/37426368PubMed
1032272980Autoimmune bullous skin diseases, pemphigus and pemphigoid.J Allergy Clin Immunol2020https://conductscience.org/library/papers/32272980PubMed
1134282745Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports.Anticancer Drugs2022https://conductscience.org/library/papers/34282745PubMed
1237438964Lenvatinib-induced pyoderma gangrenosum in a patient with hepatocellular carcinoma: A case report.J Dermatol2024https://conductscience.org/library/papers/37438964PubMed
1328155175Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.Endocrine2017https://conductscience.org/library/papers/28155175PubMed
1430236834Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.J Hepatol2018https://conductscience.org/library/papers/30236834PubMed
1531498102Pemphigus.Lancet2019https://conductscience.org/library/papers/31498102PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42819029Case Report: Lenvatinib-induced lichenoid drug reaction mimicking disseminated zoster in a patient with metastatic hepatocellular carcinoma.Front Oncol2026https://conductscience.org/library/papers/42819029

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40201353

GET https://conductscience.org/api/papers/v1/40201353/authors